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Measles cases are increasing in Ireland, with 320 cases 
notified since August 2009. Nearly two-thirds of these 
cases (n=206) were unvaccinated. In the early stages 
of  the  outbreak  a  substantial  number  of  cases  were 
linked  to  the  Traveller  community  with  some  cases 
also reported among the Roma community, other citi-
zens from eastern Europe and children whose parents 
objected to vaccination. By February 2010, there had 
been considerable spread to the general population.
Background
Measles is a highly infectious disease that can result in 
serious complications. The only way to prevent infec-
tion is through measles vaccination. Measles vaccine 
was introduced in Ireland in 1985; this was followed 
by the introduction of the combined measles-mumps-
rubella  (MMR)  vaccine  in  1988  for  children  aged  15 
months. In 1992, a second dose of MMR was recom-
mended for all children aged 10 to 14 years. In 1995, 
there was a measles and rubella vaccination campaign 
for children of primary school-age (5-12 years old). In 
1999, the age of the second dose of MMR was changed 
to 4-5 years. In 2002, the age of the first dose of MMR 
was changed to 12-15 months, and since 2008 it is rec-
ommended at 12 months of age.
In  1985,  the  year  when  measles  vaccine  was  intro-
duced, 9,903 measles cases were reported, declining to 
201 cases in 1987. However, despite the routine immu-
nisation  programme,  further  major  outbreaks  have 
occurred in 1989 (1,248 cases), 1993 (4,328 cases) and 
2000 (1,603 cases). 
Since  the  national  collation  of  quarterly  MMR1  (first 
dose)  immunisation  uptake  statistics  commenced  in 
1999, the MMR1 uptake rate in those aged 24 months 
has ranged between 69% (Quarter 4, 2001) and 91% 
(Quarter 3, 2009) [1]. While the immunisation uptake 
rate is below the target rate of 95%, measles outbreaks 
like the one seen in 2000 [2] will continue to occur. In 
addition, there are subpopulations in Ireland who are 
highly susceptible to measles, e.g. those who refuse 
the MMR vaccine and communities with low uptake of 
MMR due to social exclusion and disadvantage.
Methods
Measles figures presented in this report were based 
on  data  extracted  from  the  Computerised  Infectious 
Disease Reporting (CIDR) system on 26 February 2010 
and  are  provisional.  Incidence  rates  were  calculated 
based on population data taken from the 2006 census. 
Crude  area  rates  and  numbers  of  notified  cases  are 
shown according to the eight Health Service Executive 
(HSE) Area Departments of Public Health.
Case  classifications  are  assigned  to  notifications 
in  Ireland  as  per  the  Case  Definitions  for  Notifiable 
Diseases [3]. 
The measles case definition is as follows:
Clinical  description:  Clinical  picture  compatible  with 
measles i.e. a generalised erythematous rash lasting 
for more than three days and a temperature over 38oC 
and one or more of the following: cough, coryza (rhini-
tis), Koplik’s spots or conjunctivitis.
Laboratory  criteria  for  diagnosis  are  one  of  the 
following:
• Detection of measles IgM antibody in the absence of 
recent vaccination,
• Fourfold or higher rise in measles IgG antibody level 
in the absence of recent vaccination
• Detection of measles virus (not vaccine strains) in a 
clinical specimen.
Case classification: 
• Possible: clinically compatible cases,
•  Confirmed:  a  case  that  is  laboratory-confirmed  or 
a  clinically  compatible  case  which  is  epidemiologi-
cally linked to a confirmed case.  A laboratory-con-
firmed case does not need to meet the clinical case 
definition.
A measles case is epidemiologically linked if there was 
exposure  to  a  laboratory-confirmed  case  during  the 
infectious period (four days before to four days after 
rash  onset)  and  this  exposure  occurred  within  the 
expected incubation period of the case under investi-
gation, 7 to 18 days (mean 14 days) before rash onset.3 www.eurosurveillance.org
Epidemiology
In  week  31  in  2009  (week  ending  8  August  2009),  a 
confirmed  measles  case,  in  an  adult  who  worked  in 
a general practice, was notified in the HSE-Southern 
Area (Figure 1 shows this location). 
In week 33 in 2009, a measles case in a Roma child 
was notified in the same Area, this case’s general prac-
titioner (GP) worked in the same building as the previ-
ous case. In week 37, 2009, two measles cases, one 
in a child from the Traveller community (an indigenous 
minority group many of whom maintain a nomadic way 
of life [4]) and one in a hospital contact of this case, 
were notified in the HSE Southern Area. During weeks 
38 and 39, six cases in Travellers were notified in the 
HSE-Southern Area. From then on measles continued to 
circulate and spread to other HSE Areas. 
Although  ethnicity  is  not  routinely  collected  as  part 
of notification data and may be difficult to establish 
and  report  on,  it  was  evident  in  the  early  stages  of 
the outbreak that a substantial number of cases were 
linked to the Traveller community (anecdotal reports). 
By  December,  verbal  reports  from  the  HSE  Southern 
Area  highlighted  transmission  was  now  also  among 
children whose parents objected to vaccination, either 
for perceived safety reasons or for philosophical rea-
sons. During the course of the outbreak a small number 
of  cases  were  also  reported,  in  different  HSE  Areas, 
among  the  Roma  community  and  other  citizens  from 
Eastern Europe. By February 2010, there was consider-
able spread to the general population. 
Measles notifications from 2008 to week 7 of 2010 are 
shown in Figure 2. During weeks 1-30, 2009 43 measles 
cases  were  notified.  In  contrast,  320  measles  cases 
were notified between week 31, 2009 and week 7, 2010 
(outbreak period to date). 
Of the 320 cases notified, 227 (71%) were classified as 
confirmed  and  92  (29%)  were  classified  as  possible, 
Figure 1
Number of notified measles cases and crude incidence 
rate per 100,000 population in the eight Health Service 
Executive Area Departments of Public Health, Ireland, 
week 31, 2009 to week 7, 2010
CIR: crude incidence rate; HSE: Health Services Executive.
Figure 2
Measles notifications by week, Ireland, week 1, 2008 to week 7, 2010
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while one had no case classification specified. Measles 
notifications and crude measles incidence rates by HSE 
Area are shown in Figure 1. The majority (89%) of cases 
were under 20 years of age with the largest number of 
cases (21%) in the age group of 1-2-year-olds (Figure 3). 
The highest incidence rate was seen in those younger 
than one year (Figure 4). Of the 320 cases notified, 174 
(54%) were male and 144 (45%) were female, while sex 
was not recorded for two cases (1%). 
Of  the  320  notified  measles  cases,  206  (64%)  were 
unvaccinated; 45 (14%) were reported to have had one 
dose of MMR; six (2%) were reported to have had two 
doses of MMR and for 63 (20%) the number of doses 
of MMR was unknown/not reported. Vaccination dates 
were reported for one of the six cases with two MMR 
doses and for 36 cases with one MMR dose (nine of 
these were vaccinated less than nine days before onset 
of illness and were probably incubating measles at the 
time of vaccination). 
Of the 320 cases, 115 (36%) were hospitalised and 162 
(51%) were not hospitalised, while hospitalisation sta-
tus was unknown/not reported for 43 (13%). Length of 
Figure 4
Age specific incidence rates of measles notifications, Ireland, week 31, 2009 to week 7, 2010
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Figure 3
Measles notifications by age group and case classification, Ireland, week 31, 2009 to week 7, 2010
4
28
40
28
47
31
20
10
19
4
20
27
13
7
10
7
1
2
1
1
0
10
20
30
40
50
60
70
80
0-5     
months
6-11
months
1-2    
years
3-4    
years
5-9    
years
10-14
years
15-19
years
20-24
years
25+    
years
Unknown
Age group 
N
u
m
b
e
r
 
o
f
 
n
o
t
i
ﬁ
c
a
t
i
o
n
s
Conﬁrmed
Possible
Not speciﬁed5 www.eurosurveillance.org
hospitalisation was reported for 73 cases; the median 
duration of stay was three days (range one to 11 days).
Complications  reported  included  pneumonia  (n=16), 
ear  infection/otitis  media  (n=4),  dehydration  (n=2), 
chest infection (n=1), dehydration, nausea and vomit-
ing (n=1), pharyngitis (n=1), pneumothorax (n=1), sei-
zures (n=1) and tonsillitis (n=1).
National outbreak control team
At the start of the outbreak, a national outbreak control 
team was convened, which includes health profession-
als from the departments of public health in the HSE 
Areas, HSE-Health Protection Surveillance Centre, HSE-
National Immunisation Office, HSE Population Health, 
HSE  Social  Inclusion,  the  Institute  of  Obstetricians 
and  Gynaecologists,  the  National  Virus  Reference 
Laboratory  and    the  field  of  Paediatric  Infectious 
Disease.  This  group  agreed  public  health  strategies 
(vaccination and management of cases and close con-
tacts, awareness-raising among clinicians and commu-
nity) to control the outbreak at national and local level. 
Some of the guidance and strategies recommended by 
the outbreak control team are outlined here. 
General guidance
All  children  should  be  vaccinated  at  12  months  and 
4-5 years, as per the routine childhood immunisation 
schedule. All children who have not had two MMR vac-
cines by the age of five years should be offered vacci-
nation opportunistically. Control measures for measles 
outbreaks  were  distributed  to  various  settings  and 
healthcare staff and are available on the HPSC website 
[5]. 
Traveller community
All Traveller children who have not had two documented 
doses  of  MMR  are  recommended  MMR.  All  Traveller 
children aged 6-11 months during the current outbreak 
are  recommended  MMR  (these  children  are  also  rec-
ommended MMR again at 12 months and at 4-5 years, 
as per the normal childhood immunisation schedule). 
Traveller children who have received MMR1 are recom-
mended MMR2; MMR2 may be given one month after 
the first dose (if children under 18 months of age are 
given MMR2 less than three months after MMR1, these 
children need a third dose at 4-5 years of age). MMR 
vaccine clinics and GP sites were organised to provide 
MMR  to  the  Traveller  community.  A  subgroup  of  the 
outbreak control team was established to liaise with 
social inclusion groups and non-governmental organi-
sations  to  find  ways  to  increase  vaccination  among 
ethnic minority groups. 
Contacts of cases
MMR given within 72 hours of exposure may prevent 
infection.  Children  in  outbreak  situations  who  have 
received MMR1 are recommended MMR2; MMR2 may be 
given one month after the first dose.
Healthcare staff
All healthcare staff born since 1978 should either be 
immune to measles or have had two documented doses 
of MMR. Healthcare staff born before 1978 should be 
offered  MMR  if  they  are  considered  at  high  risk  of 
exposure. Guidance on preventing measles transmis-
sion in healthcare settings (such as rapid triage and 
case isolation in addition to vaccination) was distrib-
uted to healthcare staff and is available on the HPSC 
website [5].
MMR catch-up campaign
An MMR catch-up campaign is planned for school chil-
dren aged approximately four to 15 years (older school 
children aged were previously targeted in an MMR cam-
paign in 2009). 
Conclusion
As 29% of cases in this outbreak are currently classi-
fied  as  possible  cases,  and  although  the  laboratory 
results of some of these cases are pending at the time 
of writing, there is a continued need to strengthen mea-
sles surveillance in Ireland and ensure rigorous case 
investigation  and  laboratory  confirmation  of  all  sus-
pected measles cases. This outbreak highlights once 
again the need for an MMR vaccine uptake of at least 
95% to prevent measles outbreaks and the importance 
of increasing coverage in all groups, in particular those 
groups  who  are  hard  to  access.  The  simultaneous 
occurrence  of  the  2009  influenza  A(H1N1)  pandemic 
and the ensuing pandemic vaccination programme has 
put enormous pressure on vaccination teams trying to 
address MMR defaulters at the same time. There is a 
concern that this current outbreak may develop into a 
large outbreak similar to the one that occurred in 2000 
[2].
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Infection  with  the  recently  emerged  pandemic  influ-
enza  A(H1N1)  virus  causes  mild  disease  in  the  vast 
majority  of  cases,  but  sporadically  also  very  severe 
disease. A specific mutation in the viral haemagglu-
tinin (D222G) was found with considerable frequency 
in fatal and severe cases in Norway, but was virtually 
absent  among  clinically  mild  cases.  This  difference 
was statistically significant and our data are consist-
ent with a possible causal relationship between this 
mutation and the clinical outcome.
The 2009 influenza A(H1N1) pandemic has been char-
acterised by mild and self-limiting disease in the over-
whelming majority of cases. However, severe and fatal 
cases,  many  of  them  with  primary  viral  pneumonia, 
have been occurring in age groups where such clinical 
outcomes  are  very  rarely  seen  in  seasonal  influenza 
[1,2].  It  is  important  to  better  understand  what  viral 
and host-related factors determine this dichotomy. 
Genetic characterisation of clinical 
specimens
As part of the intensified surveillance carried out dur-
ing the current influenza pandemic, the national refer-
ence laboratory for human influenza at the Norwegian 
Institute  of  Public  Health  collected  a  large  number 
of  respiratory  specimens  from  verified  and  possible 
cases of pandemic influenza. In the present study we 
analysed  61  respiratory  specimens  from  severe  and 
fatal cases that occurred between July and December 
2009, as well as from 205 cases with mild clinical out-
comes collected between May 2009 and January 2010. 
Genetic  characterisation  was  performed  using  con-
ventional sequencing, or with a pyrosequencing assay 
subsequently developed to detect the particular muta-
tions described below and which facilitated investiga-
tion of a large number of specimens. 
Here we report the occurrence of an amino acid substi-
tution, aspartic acid to glycine in position 222 (D222G) 
in the HA1 subunit of the viral haemagglutinin, in clinical 
specimens from 11 out of 61 cases analysed in Norway 
with severe outcome. Such mutants were not observed 
in any of 205 mild cases investigated (Table), thus the 
frequency of this mutation was significantly higher in 
severe (including fatal) cases (p<0.001, Fisher’s exact 
test,  two-sided)  than  in  mild  cases.  D222G  mutants 
were  detected  throughout  the  sampling  period,  from 
the  first  recorded  severe  cases  in  July  until  early 
December.  The  frequency  of  another  substitution  in 
the same position, D222E, did not differ significantly 
between mild and severe cases (p=0.772). Yet another 
substitution, D222N, was observed in a very few cases 
(n=4), and at a higher rate than expected among severe 
cases  (three  of  four  cases,  p=0.039).  The  wild  type 
222D was, not surprisingly, significantly less frequent 
in severe than in mild cases (p<0.001).
In several of the patients where D222G mutant viruses 
were found, they coexisted with wildtype 222D viruses. 
Further analysis of this phenomenon is ongoing.
The cases infected with the D222G-mutated virus were 
not  epidemiologically  related  to  each  other,  and  the 
mutated  viruses  do  not  cluster  together  in  phyloge-
netic analysis (data not shown). 
Validity and limitations of the analysis
Cases with severe clinical outcomes were much more 
likely to be included in our study for several reasons: 
they are more likely to seek healthcare, they are more 
likely to be prioritised for virological testing, and their 
specimens  are  more  likely  to  be  forwarded  to  the 
national reference laboratory where they have a higher 
chance  of  being  selected  for  detailed  analysis  than 
viruses  from  mild  cases.  Because  of  this,  we  chose 
to  record  the  frequency  of  a  given  genotype  in  each 
severity group and compare it with the corresponding 
frequency  in  other  severity  groups.  This  approach  is 
not expected to have a selection bias. 
Cases  were  classified  as  mild,  severe  non-fatal  and 
fatal based on the patient information that was avail-
able to us. Some seemingly mild cases may later have 
exacerbated  to  severe  outcomes  without  our  knowl-
edge, or the presented patient information may have 7 www.eurosurveillance.org
been  incomplete,  but  we  think  these  cases  must  be 
few. On the other hand, all severe and fatal cases were 
confirmed  as  non-mild.  Thus,  the  fact  remains  that 
only cases confirmed as severe outcomes exhibited the 
D222G mutation in our investigation. 
The  sampling  period  for  the  cases  analysed  spans 
from the initial detections of the pandemic H1N1 virus 
in early May 2009 until early January 2010. The first 
severe and fatal cases occurred in July. By the end of 
December, the epidemic in Norway had largely passed, 
and a large proportion of cases in our data set is from 
the peak period in October and November. At all times 
an effort was made to include a reasonable number of 
non-severe cases in our analyses, and such cases were 
well  represented  throughout  the  pandemic.  The  frac-
tions of severe/fatal cases among all analysed cases 
during  the  two-month  periods  July/August  (n=21), 
September/October  (n=84),  and  November/December 
(n=149), were within the range of 23% to 26%. Severe 
outcomes were not recorded among the few cases in 
May and June (n=11) and in January (n=1). We thus do 
not see a trend over time in the composition of severe 
versus  mild  cases  in  our  dataset  that  could  lead  to 
an artificial difference in the frequency of the D222G 
substitution. Furthermore, the D222G substitution was 
represented also among the earliest fatal and severe 
cases in July and August.
Specimens from both the lower and upper respiratory 
tract  were  analysed.  Lower  respiratory  tract  speci-
mens were available from severe/fatal cases only, and 
in some cases they were the only materials available. 
However, in all cases where we had paired upper and 
lower airway specimens (five cases with 222D and four 
cases with 222G), the wildtype-versus-D222G pattern 
was matching between the locations. We have there-
fore no reason to believe that this difference in propor-
tion of lower airway specimens distorted the analysis.   
Discussion
Amino acid position 222 resides in the receptor bind-
ing site of the HA protein and may possibly influence 
the  binding  specificity  and  thus  the  cellular  tropism 
of  the  virus.  The  corresponding  difference  between 
two viruses from the 1918 Spanish influenza pandemic 
correlates to a shift in receptor preference [3], which 
conceivably  could  make  the  virus  prone  to  infect  a 
wider range of cells in the lower respiratory tract [4,5]. 
However,  the  effect  of  a  mutation  depends  on  the 
molecular context and it is unclear whether the bind-
ing properties are affected likewise in the present pan-
demic virus as they were in the 1918 influenza virus. 
Our observations are consistent with an epidemiologi-
cal  pattern  where  the  D222G  substitution  is  absent 
or  infrequent  in  circulating  viruses,  with  the  muta-
tion arising sporadically in single cases where it may 
have contributed to severity of infection. This may aid 
in filling some knowledge gaps identified in a recent 
preliminary review of this and other mutations in the 
pandemic virus [6]. The correlation between presence 
of  the  D222G  substitution  and  a  severe  clinical  out-
come may reflect an increase in pathogenicity caused 
by the mutation, possibly related to a change in cel-
lular tropism rendering the virus more pneumotropic. 
Conversely,  it  is  possible  that  the  likelihood  of  such 
mutations arising is higher in patients who fail to fight 
off  the  virus  rapidly  and  have  virus  already  colonis-
ing  the  lower  respiratory  tract.  These  two  possibili-
ties are not mutually exclusive. A large proportion of 
the fatal and severe cases had underlying risk condi-
tions. However, some of the D222G cases manifested 
themselves as a rapid unexpected deterioration after 
a period of mild symptoms in previously healthy sub-
jects, and we consider it likely that there is a causal 
relationship  between  the  occurrence  of  the  D222G 
mutation in this virus and severe disease. 
It should be borne in mind, however, that the majority 
of severe and fatal cases investigated did not carry the 
D222G substitution and, clearly, this mutation is not 
required for a severe outcome. 
Conclusions
To our knowledge, this is the first identification of a 
change  in  the  pandemic  virus  that  correlates  with  a 
severe  clinical  outcome.  However,  whereas  our  data 
lend statistically significant support to an association 
between the D222G mutation and severity, the number 
Table 
Pandemic influenza A(H1N1) viruses characterised for amino acid position 222 of the haemagglutinin HA1 domain, by 
clinical outcome, Norway, May 2009–January 2010 (n=266) 
Clinical outcomea
HA1 position 222 genotypeb Mild 
(n=205)
Severe 
(n=34)
Fatal 
(n=27)
Severe plus fatal 
(n=61)
All cases 
(n=266)
222D (wt) 92% (189) 82% (28) 59% (16) 72% (44) 88% (233)
222G 0% (0) 8.8% (3) 30% (8) 18% (11) 4.1% (11)
222E  7.3% (15) 2.9% (1) 7.4% (2) 4.9% (3) 6.8% (18)
222N 0.5% (1) 5.9% (2) 3.7% (1) 4.9% (3) 1.5% (4)
Total 100% 100% 100 % 100 % 100 %
a Clinical outcome based on patient information, assigned into categories by a medical specialist according to WHO guidance criteria [1].
b Percentage of genotype within each clinical category is given, with number of cases per category in parentheses.8 www.eurosurveillance.org
of  mild  cases  would  need  to  be  larger  to  determine 
whether  mutant  viruses  are  indeed  circulating  at  a 
very low frequency also in non-severe cases. Provided 
that  D222G  mutant  viruses  are  not  circulating,  i.e. 
that they are less transmissible, the immediate public 
health impact of this finding is limited. However, it may 
have implications for the management of severe cases 
where the virus, if transmitted through massive expo-
sure, may be more virulent than the commonly circu-
lating variant. Furthermore, it may serve as a reminder 
that the generally very low virulence of the current pan-
demic virus is not a fixed characteristic, and that there 
is no reason for complacency in carrying out measures 
that  limit  infection  with  this  virus  at  individual  and 
population level.  
Further virological, clinical and epidemiological inves-
tigations are needed to ascertain the role of this and 
other mutations that may alter the virulence and trans-
missibility of the pandemic influenza A(H1N1) virus.
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Following its detection in 2001, human metapneumo-
virus (hMPV) has repeatedly been reported as a respi-
ratory pathogen, especially in children. This study was 
aimed  at  determining  the  proportion  of  hMPV  infec-
tions in patients with influenza-like illness (ILI) during 
the three influenza seasons 2005-6, 2006-7, 2007-8 
in northern Greece. We collected 380 nasopharyngeal 
swabs or aspirates from ILI patients during the winter 
seasons 2005-2008 and examined them for influenza 
viruses and hMPV by one-step real time RT-PCR and 
nested  RT-PCR.  Influenza  viruses  were  detected  in 
151 of the 380 specimens (39.7%) and hMPV in 23 of 
them (6.05%). Co-infections with hMPV and influenza 
viruses were observed in seven cases. The majority of 
the ILI patients (60.5%) were 0-18 years old. However, 
the incidence of influenza was slightly higher in the age 
group of 19-60-year-olds, while the incidence of hMPV 
infections was higher in the age group of 0-18-year-
olds. We conclude that hMPV plays an important role 
as  a  contributor  in  influenza-like  infections,  espe-
cially in children. It circulates in the community during 
influenza seasons and its clinical appearance can be 
confused with influenza symptoms. However, further 
research is needed to elucidate the quantitative and 
qualitative importance of hMPV infections.
Introduction
In 2001, van den Hoogen et al. isolated in cultures of 
tertiary  monkey  kidney  cells  a  novel  paramyxovirus 
and identified it by random arbitrary polymerase chain 
reaction (PCR) [1]. The virus was classified tentatively 
as a new member of the genus Metapneumovirus and 
assigned  the  provisional  name  of  human  metapneu-
movirus (hMPV). Detection of viral gene sequences by 
reverse transcription-PCR (RT-PCR) directly from respi-
ratory secretions made it possible to demonstrate rap-
idly that the virus was occurring worldwide and in all 
age groups [2]. 
Influenza  viruses,  which  also  circulate  in  the  winter 
season,  are  the  leading  aetiological  agents  of  respi-
ratory tract illness in young adults [3]. In Greece, the 
influenza  season  starts  in  late  December  and  lasts 
until early April, peaking in January and February [4-6], 
and the seasonal surveillance programme on cases of 
influenza-like  illness  (ILI)  starts  earlier  in  November. 
The  National  Influenza  Centre  for  North  Greece,  one 
of two National Influenza Centres in Greece, examines 
clinical  samples  from  ILI  patients,  including  infants 
and children, every year. The sentinel surveillance sys-
tem has been responsible for ILI surveillance in Greece 
since December 1999. The collected data are reported 
by e-mail to the Hellenic Centre for Diseases Control 
and Prevention.
The aim of this study was to determine the contribu-
tion of hMPV infections to ILI during the three influenza 
seasons 2005-6, 2006-7 and 2007-8 in North Greece.
Materials and methods
During  the  three  influenza  seasons  2005-2008,  the 
National  Influenza  Centre  for  North  Greece  collected 
380  nasopharyngeal  swabs  or  aspirates  from  ILI 
patients, 214 male and 166 female patients between 
one  month  and  85  years  of  age  (mean  age  19.94 
years). Of these specimens, 158 were collected during 
the 2005-6 local influenza season, 129 in the season 
2006-7) and 93 in the season 2007-8 (Table 1). The ILI 
patients were further divided into five age groups (0-5 
years,  6-10  years,  11-18  years,  19-60  years  and  >60 
years) (Table 2). 
The specimens were collected within three days of the 
onset of symptoms by general practitioners and pae-
diatricians participating in the Greek sentinel influenza 
surveillance programme, and they were transported to 
the  laboratory  in  sucrose  phosphate  medium  within 
24 hours at a temperature of 4˚C. All specimens were 
accompanied by a sentinel standard form with informa-
tion on age, sex, date of onset, date of specimen col-
lection, place of residence and clinical features of each 
patient. All cases reported in this study met the Greek 
case  definition  for  ILI,  which  comprises  the  follow-
ing symptoms: acute onset, high fever (>38˚C), cough, 
muscle ache and/or headache and malaise. These data 
were  extracted  from  the  summaries  prepared  by  the 
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to test only the ILI cases, only patients who met these 
criteria were included. 
Virus detection and typing
Following RNA extraction from clinical specimens, one-
step real time RT-PCR for the detection of influenza A 
and B viruses was performed, using primers specific 
for  matrix  protein  and  nucleoprotein  genes  of  influ-
enza A and B [7]. To subtype the influenza A viruses, 
a nested RT-PCR was performed targeting the haemag-
glutinin  gene  using  specific  primers  provided  by  the 
Influcheck kit (Euroclone, Italy). 
For the detection of hMPV in clinical specimens, a one-
step real-time RT-PCR method was used following the 
protocol by Bonroy et al. [8].
Statistical analysis
Statistical analysis of the results was performed with 
SPSS (version 11.0). For the different age groups, the 
median age and the infection rates were estimated by 
means of descriptive statistics. The chi-square test was 
used to compare the infections rates for both influenza 
and hMPV infection among different age groups. 
Results
The median age of the 380 ILI patients was 19.94 years. 
They had mostly upper respiratory infections and none 
of  them  was  hospitalised.  Influenza  viruses  were 
detected  in  151  specimens  (39.7%)  and  hMPV  in  23 
(6.05%) (Table 1). Co-infections with hMPV and influ-
enza virus were observed in seven cases. 
In the 2005-6 season (158 ILI cases), 54 (34.1%) of the 
specimens were positive for influenza viruses (median 
age of the patients 16.6 years). The predominant type 
during that season was influenza B (44 of 54, 81.4%). 
hMPV  was  the  causative  agent  of  ILI  in  eight  cases 
(5.06%  with  median  age  of  the  patients  8.8  years). 
Co-infections with influenza virus and hMPV were iden-
tified in three of the eight cases [two with influenza B 
and one with influenza A(H3)]. 
During the 2006-7 season (129 ILI cases), 51 (39.5%) 
of the specimens were positive for influenza or hMPV 
infection.  Influenza  A(H3)  was  the  predominant  sub-
type (88.2%), while influenza B contributed to 11.7% 
of  the  infections.  hMPV  was  detected  in  eight  cases 
(6.2%) and two of them were co-infections, both with 
influenza A(H3) virus. The median age of the infected 
patients during this season was 24.1 years for influ-
enza and 10.5 years for hMPV infection. Influenza A(H1) 
was  not  isolated  in  either  of  the  winters  2005-6  or 
2006-7. 
In  the  2007-8  influenza  season,  46  of  93  specimens 
(49.4%) were positive for influenza viruses. Influenza 
A(H1)  was  the  predominant  subtype  (67.3%),  while 
influenza  B  virus  was  detected  mostly  at  the  end  of 
the season at a rate of 32.6%. Seven specimens were 
identified as positive for hMPV (7.53%) (Table 1). Viral 
co-infections between hMPV and influenza A(H1) virus 
were observed in two of the seven positive cases. The 
median age of influenza- and hMPV-infected patients 
during this season was 22.3 and 21.5 years,
According to the age distribution (Table 2), the major-
ity (n=230, 60.5%) of the ILI patients were 0-18 years 
old. Only 21 of the 380 patients examined were older 
than  60  years  (5.5%).  The  incidence  of  influenza 
infection was slightly higher in the age group of 19- 
60-year-olds,  as  58  of  the  129  influenza-infected 
Table 2
Age distribution of ILI cases and confirmed influenza virus and hMPV infections, North Greece, influenza seasons 2005-
2008 (n=380)
Age group (years) ILI cases (n) Influenza-positive (n) hMPV-positive (n)
0-5 94 23 12
7-10 82 26 4
11-18 55 37 1
19-60 128 58 5
>60 21 7 1
Total 380 151 23
hMPV: human metapneumovirus; ILI: influenza-like illness.
Table 1
Detection of influenza virus and human metapneumovirus in ILI cases, North Greece, influenza seasons 2005-2008 (n=380)
Influenza season ILI cases (n) Influenza-positive (n) Influenza A(H3) (n) Influenza A(H1) (n) Influenza B (n) hMPV (n)
2005-6 158 54 10 0 44 8
2006-7 129 51 45 0 6 8
2007-8 93 46 0 31 15 7
Total for 2005-2008 380 (100%) 151 (39.7%) 55 31 65 23 (6.05%)
hMPV: human metapneumovirus; ILI: influenza-like illness.11 www.eurosurveillance.org
patients  (44.9%)  belonged  to  this  age  group.  The 
median age of influenza- and hMPV-infected patients 
was 20.9 years and 13.6 years, respectively. The inci-
dence of hMPV infection was highest in the age group 
of  0-18-year-olds,  with  17  of  the  23  hMPV-infected 
patients (73.9%) in this age group. Finally, 16 of the 23 
hMPV-infected  patients  (69.5%)  were  under  10  years 
old. 
Statistical  analysis  of  the  results  demonstrated  that 
there was a statistically significant difference between 
the  age  groups  with  respect  to  influenza  and  hMPV 
infection in the 2005-6 season. Younger patients up to 
the age of 18 years were more likely to be infected by 
these two viruses (p=0.03 for influenza and p=0.005 
for hMPV). On the contrary, there was no statistically 
significant  difference  in  the  following  influenza  sea-
son 2006-7 in the ages of the patients with respect to 
hMPV infection (p=0.472), while there was a statisti-
cally  significant  difference  between  the  age  groups 
with respect to influenza infection, with older patients 
(19-60 years old) more likely to get influenza in that 
season  (p=0.026).  No  statistically  significant  differ-
ence between the age groups was found for influenza 
or  hMPV  infections  in  the  third  period  2007-8  (p= 
0.161  for  influenza  and  p=0.247  for  hMPV).  We  did 
not observe any statistically significant correlation of 
between sex and the probability of being infected by 
either hMPV or influenza virus (p=0.500 for influenza 
and p=0.061 for hMPV).
We further analysed the clinical severity of the 23 cases 
infected and co-infected with hMPV. The most common 
clinical  findings  in  patients  infected  only  with  hMPV 
were fever lasting on average three days (n=21), cough 
(n=18),  rhinorrhoea  (n=17)  and  wheezing  (n=15).  The 
duration  of  the  fever  was  ascertained  during  follow-
up by the physicians, done for all 23 hMPV patients to 
monitor symptoms that developed later. Chest radio-
graphs were obtained for 10 patients. Abnormal find-
ings  such  as  peribronchial  cuffing,  prominent  hilum 
and focal infiltrates were noted. It should be noted that 
the chest x-rays were taken in adults with severe symp-
toms, as radiological examination is unusual for chil-
dren with common respiratory infections as ILI in most 
European  countries.  Patients  co-infected  with  hMPV 
and influenza viruses had almost the same symptoms 
as the ones who were infected only with hMPV.
Despite the fact that none of the patients was hospi-
talised, four children with hMPV and six with influenza 
virus infection required supplemental oxygen as a pre-
ventive measure, according to the physicians attending 
to them at the outpatient clinic. Seven hMPV-infected 
children  were  treated  with  antibiotics  for  a  median 
of  five  days  (range:  1-14  days).  The  most  frequently 
reported symptoms of the eight patients aged over 60 
years (seven with influenza and one with hMPV infec-
tion) were mostly high fever over 38.5°C (n=8), muscle 
ache (n=8), dyspnoea (n=6) and sore throat (n=8). No 
hMPV-infected patient required mechanical ventilation 
or administration to the intensive care unit.
In the present study we screened only influenza virus 
and  hMPV  infections.  Co-infections  with  respiratory 
syncytial virus (RSV) and other respiratory pathogens 
require additional studies. 
Discussion
Human  metapneumovirus  is  an  emerging  pathogen 
which  has  been  associated  with  symptoms  ranging 
from mild upper respiratory tract infections to severe 
pneumonia,  exacerbation  of  asthma  and  chronic 
obstructive  pulmonary  disease  [9-14].  Serological 
studies show that the virus has been circulating unde-
tected in humans for at least 50 years [1]. It is thus an 
important pathogen and it is essential to obtain a bet-
ter understanding of its contribution to acute respira-
tory infections. 
As  the  virus  can  cause  clinical  signs  and  symptoms 
that  resemble  influenza  [15],  the  aim  of  the  present 
study  was  to  determine  the  contribution  of  hMPV  to 
ILI during the three influenza seasons 2005-8 in North 
Greece. According to our results, hMPV contributed to 
ILI at a rate of 6.05%, while influenza viruses were the 
main cause of the disease (39.7%). Although the over-
all  prevalence  of  hMPV  was  low,  it  played  an  impor-
tant role as a contributor to ILI, especially in children, 
as the majority of the hMPV-infected patients (69.5%) 
were under 10 years old. 
In the influenza season 2005-6, 5.06% of ILI patients 
were hMPV-positive, in 2006-7, it was 6.2% and 6.05% 
in 2007-8. In a similar study conducted in Japan from 
2002 to 2004, hMPV positivity rates in patients with 
ILI were 5.7% in 2002-3 and 5.2% in 2003-4 [16], while 
in another study in Finland from 2000 to 2002, hMPV 
was responsible for 7% of all respiratory infections in 
children, even though influenza was circulating in the 
community at the same time [17]. 
Co-infections of hMPV with RSV, influenza and various 
other viruses have been reported in many studies, at 
a rate of 4-70% [17]. In the present study, hMPV was 
detected in 23 ILI cases, seven of which were co-infec-
tions with influenza viruses. Co-infections with hMPV 
occurred with all the subtypes of the influenza viruses 
detected  (influenza  A(H3),  A(H1)  and  B).  As  in  previ-
ous studies, this report confirms that co-infections are 
possible, but the clinical implications of hMPV in these 
cases is still unknown, as so little is known about its 
contribution as a co-pathogen [13,14,19]. In agreement 
with the majority of studies, there was no evidence that 
patients co-infected with hMPV and influenza viruses 
had more severe disease, although Semple et al. have 
recently  suggested  that  dual  infection  by  hMPV  and 
RSV is associated with increased severity as judged by 
mechanical ventilation and intensive care unit admis-
sion [20]. 12 www.eurosurveillance.org
Our  findings  demonstrate  that  the  effect  of  hMPV 
is  greatest  in  children,  as  the  median  age  of  hMPV-
infected  patients  was  13.6  years  during  the  three 
investigated  influenza  seasons.  Sixteen  of  the  23 
hMPV-infected patients (69.5%) were under 10 years old 
and about 50% of them belonged to the age group 0-5 
years. According to previous studies, hMPV accounts 
for more than 4% of all respiratory infections in chil-
dren during the winter season and for 1-2% of all res-
piratory infections annually [16]. This estimate agrees 
with the results of a recent 20-year study in which the 
prevalence of hMPV ranged from 1% to 5% of all upper 
respiratory infections in a given year in children under 
the age of five years [21]. 
In the present study, younger patients (0-18 years old) 
were more likely to be infected by influenza virus or 
hMPV in the 2005-6 season, in contrast to 2006-7, when 
older patients (19-60 years old) had a higher probabil-
ity of getting influenza. According to information from 
the  former  European  Influenza  Surveillance  Scheme 
(EISS), the highest consultation rates for ILI during the 
2006-7 winter season were generally observed among 
children  aged  0-4  years  and  5-14  years.  However,  in 
some countries the population under surveillance was 
skewed to the younger ages (partly due to a high pro-
portion of paediatricians participating in EISS) and/or 
older ages [22].
hMPV was detected from the beginning to the end of 
each influenza season examined, and was circulating 
during the whole period. These findings are consistent 
with previous studies that demonstrate the seasonal 
distribution of hMPV infections, which resembles that 
of influenza with recurrent epidemics during the win-
ter [12,13]. In conclusion, our results show that hMPV 
is an emerging cause of acute respiratory infection in 
ILI patients and may have a significant clinical impact, 
especially  in  children.  However,  further  research  is 
needed  to  elucidate  the  quantitative  and  qualitative 
importance  of  hMPV  infection,  its  seasonal  distribu-
tion, the groups at risk of severe complications, and 
strategies for its diagnosis, treatment and prevention.
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To  the  editor:  We  read  with  particular  attention  the 
article  “Estimating  the  impact  of  the  2009  influ-
enza A(H1N1) pandemic on mortality in the elderly in 
Navarre, Spain” by Castilla and colleagues [1]. 
We were surprised by the results and conclusion of the 
authors.  They  refer  to  a  significant  excess  of  deaths 
(Table  1:  +4.9%,  p=0.0268)  among  adults  aged  65 
years or older during the pandemic period (weeks 24 to 
52, 2009). When considering the average annual mor-
tality rate for 2006–2008 compared to the same rate 
in 2009, the excess of deaths is non-significant (Table 
1: +2%, p=0.47). Because of the marked growth of the 
elderly population (the authors mention an increase of 
10% in people aged 85 and more from 2006 to 2009), it 
would be preferable to use mortality rates rather than 
the numbers of deaths to compare the observed with 
the estimated deaths. 
In Table 2, the authors estimate a significant excess of 
mortality of 9.9% in the population aged 65 years or 
older during the 12-week first pandemic wave (weeks 
24 to 35) and a new non-significant excess of mortality 
during the second 10-week pandemic wave (weeks 40 
to 49). If we compare those two periods on a weekly 
basis we observe 56 deaths per week (weeks 24 to 35) 
and 60 deaths per week (weeks 40 to 49). The authors 
report  208  cases  of  pandemic  influenza  A(H1N1)  per 
week and 1,757 cases of pandemic influenza A(H1N1) 
per week, respectively, for these periods (Table 2). It 
would appear strange to have 1.07 times more deaths 
per week while at the same time 8.5 times more cases 
of influenza were observed per week. Furthermore, the 
numbers  for  laboratory-confirmed  cases  of  influenza 
presented in Table 2 are higher in week 40 to 49 than 
for all other periods, which is not consistent with the 
conclusions.  In  the  same  table,  the  authors  show  a 
decrease of 4% in the number of deaths between week 
36 and 39 during which 52 deaths per week and 346 
cases of influenza per week were observed (see Table 
2) but do not elaborate on those results. 
The authors do not provide information about the per-
centage of the population aged 65 years or older in the 
number of cases during the two pandemic waves, while 
it is known that the elderly seem to have suffered less 
from  the  2009  influenza  pandemic  than  the  younger 
adults [2-3].
In the Figure, the weekly observed number of deaths is 
higher than the expected number of deaths from week 
24 to week 35 (summer period). The authors mention 
that  the  heat-alert  threshold  in  their  region  was  not 
reached during the summer, while it is known that a 
slight increase in mortality is possible even if temper-
atures  remain  below  the  heat-alert  threshold.  In  the 
summer  period,  temperatures  and  mortality  fluctua-
tions are closely related   and temperatures just below 
the  heat-alert  threshold  can  have  already  a  marked 
effect on mortality among the elderly [4]. We wonder 
whether  the  observed  temperatures  during  the  sum-
mer 2009 were more elevated than those recorded dur-
ing  the  three  previous  summers,  which  would  partly 
explain  the  inconsistency  of  the  observed  mortality 
results during the two pandemic waves?
The Poisson fluctuation interval around the observed 
weekly numbers of deaths would have facilitated the 
identification of the weeks in which there was a statis-
tically significant excess of deaths.
As the study was done on the basis of all-cause mor-
tality data, it is difficult to deduce a causal relation-
ship between pandemic influenza and mortality in our 
opinion. A temporal relationship should have been dis-
cussed more in-depth. The monitoring of mortality is a 
part of measuring the burden of disease in a popula-
tion and needs to be done cautiously.
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To  the  editor:  We  appreciate  the  comments  by
L Josseran and A Fouillet [1] and agree with many of 
them. A number of the aspects they comment on were 
mentioned  in  our  work,  but  we  appreciate  having 
another opportunity to discuss them.  
Demonstrating the impact of influenza on general mor-
tality entails considerable difficulty, and has been the 
object of interesting methodological discussions [2,3]. 
The difficulty lies largely in finding an adequate base-
line reference for the comparison, ruling out the effect 
of  other  causes.  An  ecological  study  like  ours,  con-
ducted in a small region, has limited capacity to pro-
vide definitive evidence for this association. Aware of 
this limitation, we restrict ourselves to describing the 
excess mortality observed in older people coinciding 
with the weeks of highest circulation of the pandemic 
influenza – and for which we have found no other argu-
ments that could completely explain it. Similar excess 
mortality has also been observed to coincide with cir-
culation of the seasonal influenza virus, but not in peri-
ods with little or no influenza activity. 
In table 1 we showed the comparison between observed 
and expected values, both for the number of cases and 
for the crude and adjusted rates. Coinciding with the 
downward secular trend in mortality, the crude rate in 
the period before circulation of pandemic influenza was 
1.3% lower than expected, despite ageing of the popu-
lation, and the standardised mortality ratio indicated a 
reduction of 4%. In contrast, the crude rate observed 
in the pandemic period was 2% higher than expected, 
and the standardised mortality ratio of 1 indicated a 
stabilisation. We suggested that this different trend in 
the pandemic period could be related with the circula-
tion of 2009 influenza A(H1N1).
The  deaths  occurring  during  the  summer  were  com-
pared  with  those  of  other  summers  when  influenza 
activity was not detected, which facilitates detection of 
the impact of influenza on mortality, in the event that 
it occurred. In contrast, the deaths that occurred from 
week 47 on were compared with those of weeks with 
some influenza activity in previous years. Thus, only if 
the impact of influenza on mortality is greater in the 
study year than in the reference years, can we say that 
there was an excess of deaths. In any case, mortality 
during the second pandemic wave was higher than in 
the first, which is consistent with the incidence of med-
ically-attended influenza-like illness (MA-ILI). 
In weeks 36 to 39 we continued to detect a non-negligi-
ble incidence of MA-ILI, but only 3% of the cases ana-
lysed were positive for influenza virus, indicating low 
virus circulation.
In 2009 the weekly or daily mortality thresholds were 
exceeded  in  June,  July  and  August.  In  June  and  July 
the mean maximum and minimum temperatures were 
not  significantly  different  from  the  means  for  the 
same months in the three previous years. In August, 
however, the mean maximum temperature was 4.0  oC 
higher (30.8 versus 26.8) and the mean minimum was 
1.5 0C higher (15.8 versus 14.3) with respect to the three 
previous years, although at no time did it exceed the 
thresholds established for a heat alert. Daily mortality 
exceeded the threshold of deaths on six occasions dur-
ing the summer of 2009, but on only two of them had 
the temperatures in the three previous days exceeded 
a maximum of 33  0C or a minimum of 18  0C. Although 
we do not totally rule out the effect of heat on mortality 
during the summer of 2009, it does not appear to com-
pletely explain the excess mortality detected.  
The incidence of MA-ILI in persons aged 65 and older 
was 0.73 per 1,000 during the first pandemic wave and 
3.67 per 1,000 in the second wave. Nonetheless, the 
repercussion of influenza on mortality in older people 
may be partly due to deaths in persons not previously 
diagnosed with ILI. 
Finally, there are some arguments that would explain 
a certain impact of the influenza A(H1N1) pandemic on 
mortality  in  older  people  that  may  have  gone  unno-
ticed.  The  incidence  of  seasonal  influenza  is  usually 
low in the elderly, but when its impact on mortality is 15 www.eurosurveillance.org
evaluated, relatively high values with respect to inci-
dence  are  generally  estimated.  Mortality  from  pan-
demic A(H1N1) influenza has been evaluated in several 
studies,  but  most  of  them  have  focused  on  deaths 
occurring in laboratory-confirmed cases [4-5]. Although 
the number of influenza tests has increased greatly, it 
is still small in relation to the number of MA-ILI cases. 
Previous  studies  have  suggested  that  influenza  can 
trigger or exacerbate non-infectious pathologies such 
as cardiovascular diseases [6], and influenza may be 
hidden by the underlying pathology. It is also possible 
that some of the influenza-related deaths occurred out-
side the hospital.
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